Earlier today, Sun Pharma announced the launch of BromSite™ (bromfenac ophthalmic solution) 0.075% — a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery — in the U.S. market.
Approved by the U.S. FDA on April 8, 2016, BromSite is reportedly the first NSAID approved to prevent ocular pain and treat inflammation in the eye following cataract surgery. The product will be marketed by Sun Ophthalmics, the company's branded ophthalmic business division. And BromSite is reportedly the first branded product launched by the company in the U.S., following its focus on Specialty Business.
Click here to read the full press release.